Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

Recurrent GBM efficacy

Optune monotherapy delivered comparable efficacy vs
chemotherapy*

OS in EF-11, the pivotal phase 3 trial1

Overall survival in EF-11, the pivotal phase 3 trial graph

*Therapy options were the physican's best choice for chemotherapy, including bevacizumab, which were defined given historical assessment of effective recurrent GBM therapies. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.

Twice as many patients responded to Optune vs physician’s choice of chemotherapy3

Optune
(n=120)
Chemotherapy*
(n=117)
Complete Response 3 (3) 0
Partial Response 11 (9) 7 (6)
Median Time to Response,
months (95% CI)
8.4 (6.9-9.9) 5.8 (3.6-8.0)
Median Response Duration,
months (95% CI)
7.3 (0.0-16.6) 5.6 (3.8-7.5)

OS correlated with treatment compliance in a subgroup analysis of patients treated with Optune2

Subgroup analysis of glioblastoma (GBM) patients treated with Optune®

  • OS was significantly higher in patients who received Optune for ≥18 hours per day (n=92) vs those who received therapy for <18 hours per day (n=28), 7.7 months vs 4.5 months, respectively (P=0.0042)2

  • Median compliance was 86% (range 41%-98%) of the time in each treatment month, translating into a mean use of 20.6 hours per day1

CI, confidence interval; GBM, glioblastoma; HR, hazard ratio; ITT, intent to treat; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression-free survival; PFS6, progression-free survival at 6 months; QoL, quality of life.

References: 1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2­1­9­2­-­2­2­0­2. 2. Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy. Semin Oncol. 2014;41(suppl 6):S25-S34. 3. Wong ET, Lok E, Swanson KD, et al. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Med. 2014;3(3):5­9­2­-­6­0­2.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).